155 related articles for article (PubMed ID: 2270941)
1. Human isophane or lente insulin? A double blind crossover trial in insulin dependent diabetes mellitus.
Gibb DM; Foot AB; May B; Parish H; Strang S; Grant DB; Dunger DB
Arch Dis Child; 1990 Dec; 65(12):1334-7. PubMed ID: 2270941
[TBL] [Abstract][Full Text] [Related]
2. Double-blind crossover trial of isophane (NPH)- and lente-based insulin regimens.
Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
Diabetes Care; 1989 Feb; 12(2):115-9. PubMed ID: 2649324
[TBL] [Abstract][Full Text] [Related]
3. Split-mixed insulin regimen with human ultralente before supper and NPH (isophane) before breakfast in children and adolescents with IDDM.
Wolfsdorf JI; Laffel LM; Pasquarello C; Vernon A; Herskowitz RD
Diabetes Care; 1991 Nov; 14(11):1100-6. PubMed ID: 1797498
[TBL] [Abstract][Full Text] [Related]
4. The contribution of intermediate-acting insulin preparations to daytime insulin treatment.
Robert JJ; Chevenne D; Debray M
Diabet Med; 1989 Aug; 6(6):531-6. PubMed ID: 2527136
[TBL] [Abstract][Full Text] [Related]
5. A comparison of human ultralente- and lente-based twice-daily injection regimens.
Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
Diabet Med; 1989 Aug; 6(6):496-501. PubMed ID: 2527130
[TBL] [Abstract][Full Text] [Related]
6. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
7. Glycaemic control and hypoglycaemia in children, adolescents and young adults with unstable type 1 diabetes mellitus treated with insulin glargine or intermediate-acting insulin.
Herwig J; Scholl-Schilling G; Böhles H
J Pediatr Endocrinol Metab; 2007 Apr; 20(4):517-25. PubMed ID: 17550216
[TBL] [Abstract][Full Text] [Related]
8. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes.
Heller SR; Colagiuri S; Vaaler S; Wolffenbuttel BH; Koelendorf K; Friberg HH; Windfeld K; Lindholm A
Diabet Med; 2004 Jul; 21(7):769-75. PubMed ID: 15209772
[TBL] [Abstract][Full Text] [Related]
9. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
10. Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus.
Thalange N; Bereket A; Larsen J; Hiort LC; Peterkova V
Pediatr Diabetes; 2011 Nov; 12(7):632-41. PubMed ID: 21418455
[TBL] [Abstract][Full Text] [Related]
11. Clinical usefulness of serum fructosamine and HbA1 as markers for metabolic control in patients with changing insulin regimens.
Steen G; Weber RF
Diabetes Res; 1990 Apr; 13(4):177-82. PubMed ID: 2134209
[TBL] [Abstract][Full Text] [Related]
12. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin.
Riccio A; Avogaro A; Valerio A; Zappella A; Tiengo A; Del Prato S
Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521
[TBL] [Abstract][Full Text] [Related]
13. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
Fulcher GR; Gilbert RE; Yue DK
Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes.
Pieber TR; Eugène-Jolchine I; Derobert E
Diabetes Care; 2000 Feb; 23(2):157-62. PubMed ID: 10868824
[TBL] [Abstract][Full Text] [Related]
15. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.
Kølendorf K; Ross GP; Pavlic-Renar I; Perriello G; Philotheou A; Jendle J; Gall MA; Heller SR
Diabet Med; 2006 Jul; 23(7):729-35. PubMed ID: 16842476
[TBL] [Abstract][Full Text] [Related]
16. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus.
Schober E; Schoenle E; Van Dyk J; Wernicke-Panten K;
J Pediatr Endocrinol Metab; 2002 Apr; 15(4):369-76. PubMed ID: 12008682
[TBL] [Abstract][Full Text] [Related]
17. Influence of human insulin on symptoms and awareness of hypoglycaemia: a randomised double blind crossover trial.
Egger M; Smith GD; Teuscher AU; Teuscher A
BMJ; 1991 Sep; 303(6803):622-6. PubMed ID: 1932903
[TBL] [Abstract][Full Text] [Related]
18. Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes.
White NH; Chase HP; Arslanian S; Tamborlane WV;
Diabetes Care; 2009 Mar; 32(3):387-93. PubMed ID: 19106380
[TBL] [Abstract][Full Text] [Related]
19. Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus.
Chase HP; Arslanian S; White NH; Tamborlane WV
J Pediatr; 2008 Oct; 153(4):547-53. PubMed ID: 18589448
[TBL] [Abstract][Full Text] [Related]
20. Different daily blood glucose control and free insulin levels during treatment with mixtures of soluble and lente or soluble and NPH semisynthetic human insulins.
Cucinotta D; Di Benedetto A; Gigante A; Di Cesare E; Musolino C; Squadrito G
Diabete Metab; 1989; 15(4):182-7. PubMed ID: 2680669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
